Upadacitinib to improve anxiety in patients with adalimumab-treated psoriatic arthritis: study protocol for a randomized controlled trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Upadacitinib to improve anxiety in patients with adalimumab-treated psoriatic arthritis: study protocol for a randomized controlled trial ; volume:25 ; number:1 ; day:5 ; month:9 ; year:2024 ; pages:1-9 ; date:12.2024
Trials ; 25, Heft 1 (5.9.2024), 1-9, 12.2024
- Urheber
-
Liao, Junlan
Wang, Ziyu
Zhang, Jianyong
Tan, Haibo
Zhang, Zhihao
Zhang, Shan
Hu, Shasha
Geng, Hongling
Zhan, Zhiying
Wei, Jiaxin
Li, Zhiling
Jia, Ertao
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13063-024-08429-7
- URN
-
urn:nbn:de:101:1-2411212225391.352059453550
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Liao, Junlan
- Wang, Ziyu
- Zhang, Jianyong
- Tan, Haibo
- Zhang, Zhihao
- Zhang, Shan
- Hu, Shasha
- Geng, Hongling
- Zhan, Zhiying
- Wei, Jiaxin
- Li, Zhiling
- Jia, Ertao
- SpringerLink (Online service)
Ähnliche Objekte (12)
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
Rheumatoide Arthritis: Upadacitinib im Vergleich gegen Plazebo und Adalimumab
Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient
Refractory necrotizing scleritis successfully treated with adalimumab
Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
IgA Nephropathy in a Patient Treated with Adalimumab
Duodenal Crohn’s disease successfully treated with adalimumab
Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation
Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
Rheumatoide Arthritis: Upadacitinib im Vergleich gegen Plazebo und Adalimumab
Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient
Refractory necrotizing scleritis successfully treated with adalimumab
Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
IgA Nephropathy in a Patient Treated with Adalimumab
Duodenal Crohn’s disease successfully treated with adalimumab
Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation
Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis
Addition or removal of concomitant methotrexate alters adalimumab effectiveness in rheumatoid arthritis but not psoriatic arthritis
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
Rheumatoide Arthritis: Upadacitinib im Vergleich gegen Plazebo und Adalimumab
Lymph node and pulmonary tuberculosis during upadacitinib treatment in a psoriatic arthritis patient
Refractory necrotizing scleritis successfully treated with adalimumab
Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
IgA Nephropathy in a Patient Treated with Adalimumab
Duodenal Crohn’s disease successfully treated with adalimumab
Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation
Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis